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ABSTRACT Staphylococcus pseudintermedius causes opportunistic infections in dogs.
It also has significant zoonotic potential, with the emergence of multidrug resistance
leading to difficulty treating both animal and human infections. Manuka honey has
previously been reported to inhibit many bacterial pathogens, including methicillin-
resistant Staphylococcus aureus, and is successfully utilized in both clinical and veteri-
nary practice. Here, we evaluated the ability of manuka honey to inhibit strains of S.
pseudintermedius grown alone and in combination with antibiotics, as well as its ca-
pacity to modulate virulence within multiple S. pseudintermedius isolates. All 18 of
the genetically diverse S. pseudintermedius strains sequenced and tested were inhib-
ited by 12% (wt/vol) medical-grade manuka honey, although tolerance to five clini-
cally relevant antibiotics was observed. The susceptibility of the isolates to four of
these antibiotics was significantly increased (P  0.05) when combined with sub-
lethal concentrations of honey, although sensitivity to oxacillin was decreased. Viru-
lence factor (DNase, protease, and hemolysin) activity was also significantly reduced
(P  0.05) in over half of isolates when cultured with sublethal concentrations of
honey (13, 9, and 10 isolates, respectively). These findings highlight the potential for
manuka honey to be utilized against S. pseudintermedius infections.
IMPORTANCE Staphylococcus pseudintermedius is an important member of the skin
microbial community in animals and can cause opportunistic infections in both pets
and their owners. The high incidence of antimicrobial resistance in S. pseudinterme-
dius highlights that this opportunistic zoonotic pathogen can cause infections which
require prolonged and intensive treatment to resolve. Manuka honey has proven ef-
ficacy against many bacterial pathogens and is an accepted topical treatment for in-
fections in both veterinary and clinical practice, and so it is a particularly appropriate
antimicrobial for use with zoonotic pathogens such as S. pseudintermedius. Here, we
demonstrate that not only is manuka honey highly potent against novel multidrug-
resistant S. pseudintermedius isolates, it also acts synergistically with clinically rele-
vant antibiotics. In addition, manuka honey modulates S. pseudintermedius virulence
activity, even at subinhibitory concentrations. In a clinical setting, these attributes
may assist in controlling infection, allowing a more rapid resolution and reducing
antibiotic use.
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Staphylococcus pseudintermedius is a commensal bacterium of the skin and mucousmembranes of up to 80% of dog populations (1) and is frequently associated with
opportunistic veterinary infections such as postsurgical infections and pyoderma (2, 3).
Increasingly, methicillin-resistant S. pseudintermedius (MRSP) is being isolated from
these infections, and reports now indicate that S. pseudintermedius isolates display
resistance to a range of antibiotics, including erythromycin, clindamycin, ciprofloxacin,
and gentamicin (4). This resistance to multiple classes of antibiotics has made S.
pseudintermedius a global clinical challenge in veterinary medicine, as treatment of
infections is increasingly problematic. The prevalence of S. pseudintermedius has impli-
cations that reach beyond the veterinary field, as studies have shown that S. pseudin-
termedius can cause zoonotic infections in humans, making it a significant health issue
(5, 6).
The zoonotic potential of this organism has only recently been recognized because
S. pseudintermedius infections in humans have previously been misidentified as Staph-
ylococcus aureus due to their phenotypic similarities and coagulase positivity (7). These
species share traits such as acquired methicillin resistance, ability to form biofilms,
modulation of the host immune system, and production of proteolytic enzymes and
toxins (8). Recent advances in diagnostics have allowed clearer separation of the two
species and have shown that, as well as being a zoonotic agent, S. pseudintermedius is
able to colonize the nasal passageways of humans. This colonization provides a
reservoir for reinfection of both animals and humans, and a potential reservoir for
antimicrobial resistance gene transfer (9). As S. pseudintermedius has exhibited a
decreasing level of antibiotic susceptibility and can cause severe infection in both
animals and humans, there are grounds for evaluating whether new strategies or novel
antimicrobial agents could be used to enhance treatment options (10).
Manuka honey is used as a topical antimicrobial agent for infections in both humans
and animals, exhibiting activity against a wide range of pathogens (11). Antimicrobial
activity is due to the presence of multiple antimicrobial compounds within the honey,
the best studied of which is methylglyoxal, together with a high osmotic potential (for
a review of the activity of manuka honey, see reference 12). Manuka honey has been
used to successfully eradicate S. aureus infections in the clinic and can inhibit the
growth of methicillin-resistant S. aureus (MRSA) and Pseudomonas aeruginosa at low
concentrations in vitro (13, 14). The mode of action of manuka honey against MRSA has
been partially elucidated, and, due to the phenotypic similarity between S. aureus and
S. pseudintermedius, is highly likely to be similarly effective in inhibiting S. pseudinter-
medius and MRSP (15). More recent studies have also highlighted the ability of manuka
honey to increase efficacy of some clinically relevant antibiotics against MRSA, which
could also be useful in the case of difficult-to-treat antibiotic-resistant S. pseudinterme-
dius infections (15). In parallel, manuka honey has been utilized by the veterinary
community, in particular for treatment of equine wounds (16). Previous work has
demonstrated in vitro activity against a wide range of equine bacterial isolates (17) with
in vivo activity also recently reported (18).
Here, we aimed to establish whether manuka honey could inhibit the growth of a
range of genetically diverse S. pseudintermedius strains, increase the sensitivity of
clinical S. pseudintermedius isolates to a range of antibiotics, and reduce expression of
key virulence factors. Activity in these areas would indicate potential for manuka honey
in the treatment of difficult-to-treat infections caused by S. pseudintermedius.
RESULTS
Genome sequencing showed isolates were genetically diverse and contained
novel MLST sequences. As these isolates have not previously been reported, they
were sequenced in order to interrogate their multilocus sequence typing (MLST) and
antimicrobial resistance (AMR) profiles and to detect how closely related the isolates
were genetically. Sequencing reads and genome assemblies from this study are avail-
able from NCBI via the BioProject record PRJNA561036. MLST allele sequences were
derived from assemblies and submitted to the Staphylococcus pseudintermedius Pub-
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MLST database. New allele sequences were detected for the pta locus of isolate C and
the ack locus of isolate G. A total of 10 novel sequence types (STs) were identified
within this data set, with a further 8 STs identified, 4 of which belonged to ST71
(assembly and MLST information can be found in Table S1 in the supplemental
material). A summary of the different antibiotic resistance genes present in each
isolate can be seen in Table 1.
A core genome SNP phylogeny accounting for the removal of detected recombi-
nation and consisting of the isolates documented within this study, along with Staph-
ylococcus pseudintermedius genome assemblies, displayed very little obvious clustering
of isolates based on geographical location or the health status of the individual from
which they were isolated (Fig. 1).
Minimum inhibitory/bactericidal concentration testing of honey and antibiot-
ics showed universal activity of honey against the S. pseudintermedius isolates
tested. Previous work by our group indicates that manuka honey has antibacterial
activity against Staphylococcus sp., including antibiotic-resistant (AR) isolates (11, 13). In
this study, all 18 isolates of S. pseudintermedius demonstrated susceptibility to low
concentrations of manuka honey (12% [wt/vol]), with 9/18 inhibited at 12% (wt/vol)
and 9/18 inhibited at 10% (wt/vol) manuka honey. No antimicrobial activity was
detected at concentrations of less than 8% (wt/vol) manuka honey. The minimum
bactericidal concentration was 12% (wt/vol) manuka honey for all isolates.
The sensitivity of the S. pseudintermedius isolates to tetracycline, penicillin, chlor-
amphenicol, gentamicin, and oxacillin was also determined. For tetracycline, penicillin,
and gentamicin, more than half of the isolates tested (9, 16, and 11 isolates, respec-
tively) had breakpoints that indicated resistance according to the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Only chloramphenicol and
oxacillin remained effective against a majority of isolates, with 10 and 14 isolates,
respectively, remaining susceptible.
Assessment of antibiotic interactions showed that honey was able to increase
the activity of the majority of antibiotics tested. There has been significant recent
interest in combination therapy, i.e., combinations of antibiotics with other antibiotics,
peptides, and plant extracts, to increase antibiotic efficacy (19, 20). Since the isolates
within the collection tested here display a high level of resistance to commonly used
antibiotic treatments, it was speculated that antibiotic efficacy might be improved if
used in combination with sublethal concentrations of manuka honey.
Manuka honey increased the sensitivity of a number of isolates to various antibiot-
ics, with small but statistically significant increases in zone size observed for the
TABLE 1 Summary of the antibiotic resistance genes found by sequencing of each isolate
Isolate
identity
Gene(s) by antibiotic class
Aminoglyocoside Beta lactam Chloramphenicol Macrolide Streptothricin Tetracycline Trimethoprim
A
B blaI, blaPC1
C blaI, blaR1, blaZ tet(M)
D aph(3”)-IIIa, ant(6)-Ia blaPC1, blaR1 tet(M)
E blaI, blaPC1 sat4 tet(M)
F blaI, blaR1
G
H aph(3”)-IIIa, ant(6)-Ia blaI, blaR1, blaZ catA7 erm(B) sat4 tet(M)
I aph(3”)-IIIa, ant(6)-Ia blaI, blaR1 erm(B) sat4
J
K blaI, blaR1, blaZ tet(M)
M blaI, blaPC1, blaR1 tet(M)
N aph(3”)-IIIa, ant(6)-Ia blaI, mecA, mecI, mecR1 erm(B) sat4 dfrG
O aph(3”)-IIIa, ant(6)-Ia blaI, blaZ catA7 erm(B) sat4
P aph(3”)-IIIa, ant(6)-Ia blaI, blaPC1, blaR1, mecA, mecI, mecR1 erm(B) sat4 dfrG
Q aph(3”)-IIIa blaI, blaR1, mecA, mecI, mecR1 erm(B) sat4 tet(K) dfrG
T aph(3”)-IIIa, ant(6)-Ia blaI, blaR1, mecA, mecI, mecR1 erm(B) sat4 dfrG
X aadE blaI, blaPC1, blaR1 erm(B) tet(M), tet(O)
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majority of isolates (Fig. 2, Fig. S1). The exact increase in susceptibility was both strain
and antibiotic specific. Full details of the inhibition of each isolate to the five antibiotics
with and without honey are shown in Fig. S1. The numbers of isolates which displayed
significantly larger zones of inhibition (P  0.05) when treated with sublethal concen-
trations of honey (5% [wt/vol]) combined with antibiotic compared to antibiotic alone
were as follows: tetracycline 89% (16/18), penicillin 56% (10/18), chloramphenicol 83%
(15/18), and gentamicin 67% (12/18). In some instances (isolates C, D, E, K, M, and X for
tetracycline and isolates O and X for chloramphenicol), the isolates showed complete
resistance to the antibiotic in standard medium; however, in the presence of subin-
hibitory honey, a zone of inhibition was present. When manuka honey was used in
combination with oxacillin, none of the isolates displayed increased sensitivity and 33%
(6/18) isolates showed significantly decreased sensitivity (Fig. 2, data for individual
isolates in Fig. S1).
Generally, there was a good correlation between the AMR phenotype observed in
the disc diffusion assays and the genotype of each isolate. There were several instances
where discrepancies between genotype and phenotype were detected, but only two
are of note. First, no beta lactam-inhibiting genes were detected in isolate G, despite a
clear phenotypic resistance to penicillin but not oxacillin. There was a similar observa-
tion for isolate X, which was phenotypically resistant to chloramphenicol despite no
identifiable resistance gene identified encoding chloramphenicol inactivation enzymes
(acquired genes) (Table S1). Thus, in this case, 50S ribosomal subunit mutational effects
are the likely source of resistance.
Characterization of virulence factor activity indicated that manuka honey was
able to reduce activity of several key virulence factors. Alongside its antimicrobial
FIG 1 A maximum likelihood phylogeny of 156 Staphylococcus pseudintermedius isolates reconstructed from core SNPs, with removal of detected recombination
sites. Samples sequenced in this study are distributed across the tree as noted by the outer black triangles. Colored bars indicate geographical locations of
isolation sources. Isolates with metadata related to host health have terminal nodes colored green for healthy or red for confirmed infection.
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activity, manuka honey has previously been shown to affect protein and gene expres-
sion in the closely related species S. aureus (21). It was therefore of interest to determine
if manuka honey could elicit phenotypic changes in the virulence profile of S. pseud-
intermedius isolates. Initially the hemolytic, protease, lipase, and DNase activities of the
isolates were assessed without manuka honey, alongside the isolate’s ability to aggre-
gate (a property linked to biofilm formation).
All 18 isolates showed hemolytic, proteolytic, DNase, and aggregation activities.
None of the isolates demonstrated lipase or lecithinase capabilities (data not shown).
The activity was then reassessed using a sublethal concentration (5% [wt/vol]) of
manuka honey. As with the antibiotic activity (Fig. 2), the presence of subinhibitory
concentrations of honey were able to elicit alterations in the virulence activity of the S.
pseudintermedius isolates. As with the alterations in antibiotic susceptibility, alterations
in virulence activity appeared to be highly isolate specific. In most of the isolates the
observed effects were subtle, although statistically significant. However, four of the
strains showed a complete reduction of hemolysis (strains G and H) or proteolysis
(strains B and C) activity. Two further strains (D and F) showed complete reduction of
both hemolysis and proteolysis. The numbers of isolates which had significantly
FIG 2 Zone diameters of inhibition. Panels A to E show zone diameters (in mm) with chloramphenicol, gentamicin,
oxacillin, penicillin, and tetracycline, respectively, against 18 isolates of S. pseudintermedius in MHB (control) versus
a sublethal concentration of manuka honey, 5% (wt/vol) (treated). Those isolates showing significant changes in
sensitivity are marked with asterisks (**, P  0.01; ***, P  0.001; ****, P  0.0001). Data points show median values
and error bars represent the 95% confidence limit.
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changed (P  0.05) hemolysis, proteolysis, and DNase activities when grown in a
sublethal concentration of honey (5% [wt/vol]) compared to control cells were hemo-
lytic 56% (10/18), protease 50% (9/18), and DNase 72% (13/18) (Fig. 3, Fig. S2).
Subinhibitory concentrations of manuka honey inhibited aggregation and
reduced mature biofilm biomass of S. pseudintermedius suspensions. All 18 isolates
displayed the ability to agglutinate. After 24 h of incubation, control isolates had a
mean optical density at 600 nm (OD600) of 25% of the 0-h value, indicating that
bacterial cells had agglutinated, leading to a decreased OD600 (Fig. 4A). In contrast, 15
of the isolates displayed a significantly reduced (P  0.001) ability to agglutinate after
incubation with a sublethal (5% [wt/vol]) concentration of honey, with a mean optical
density of 65% of the 0-h value (Fig. 4A). Total viable cell counts after 24 h of incubation
with and without manuka honey highlighted that the increased optical density was not
linked to an increase in cell numbers, with total viable counts indicating that 4  107
CFU/ml viable cells remained in each vessel following incubation. With the exception of
isolates B and H, which were moderate biofilm formers, and isolate O, which was a weak
biofilm former, all the isolates were strong biofilm formers as defined by Stepanovic et
al. (22).
As expected, the concentrations of manuka honey needed to disrupt established
(24 h) biofilm were higher than the MIC (Fig. 4B). There was a reduction in biomass at
FIG 3 Manuka honey is able to inhibit virulence factor production by S. pseudintermedius. DNase (A),
hemolytic (B), and proteolytic (C) activities of the 18 S. pseudintermedius isolates in the absence (control)
or presence (treated) of a sublethal (5% [wt/vol]) concentration of manuka honey. Those isolates showing
significant changes in sensitivity are marked with asterisks (**, P  0.01; ****, P  0.0001). Data points
show median values and error bars represent the 95% confidence limit.
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concentrations of 20% (wt/vol) manuka honey, with reductions becoming signif-
icant (P  0.01) at concentrations of 30%.
DISCUSSION
The increase in S. pseudintermedius antibiotic resistance is of concern to both
clinicians and veterinarians (23, 24). New strategies for infection control are required
and a One Health approach must be utilized during discovery to ensure that thera-
peutics can be used harmoniously across medical disciplines. Clinicians and veterinar-
ians have previously been criticized for excessive use of antibiotics (25), and following
the publication of the “Review on Antimicrobial Resistance” (chaired by Jim O’Neill) (26)
there has been a drive to improve collaboration between medical, veterinary, and
agricultural disciplines (27) in addressing the issue of AMR. The report by O’Neill (26)
also highlighted that the development of novel therapeutics to enhance the activity of,
or replace, antibiotic treatments was an essential strategy to preserve our ability to
effectively treat infectious diseases.
Zoonotic pathogens are of concern, since inappropriate treatment and resolution of
animal infections has the potential to increase disease severity and recalcitrance to
treatment of any subsequent human infection. Other members of the Staphylococcus
genus, such as S. aureus and S. epidermidis, are persistent colonizers of the human body,
causing significant morbidity and mortality, and display high levels of AMR. S. pseud-
intermedius has also been shown to colonize healthy humans (28) and appears to have
similar disease progression and resistance patterns to other members of the genus (23,
24, 29).
The S. pseudintermedius strains in this study showed a wide range of genetic
diversity (Fig. 1), including the presence of several novel MLST combinations. The
genetic diversity of these samples allowed an estimation of how effective manuka
FIG 4 The ability of S. pseudintermedius isolates to aggregate is reduced in the presence of subinhibitory
5% (wt/vol) manuka honey. (A) Effect of sublethal (5% [wt/vol]) manuka honey on 18 S. pseudintermedius
isolates. Isolates showed a significant decrease (P  0.001) in their ability to aggregate when treated with
5% (wt/vol) manuka honey. (B) Effect of increasing concentrations of manuka honey on preformed 24-h
biofilms with a significant (**, P  0.01; ***, P  0.001) reduction in biofilm seen at concentrations of
30% (wt/vol). Data points indicate median values and error bars represent the 95% confidence limit.
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honey might be for treatment of S. pseudintermedius infections, as multiple strains of S.
pseudintermedius with varied antibiotic resistance profiles can cocolonize at an infection
site (30). The majority of isolates also contained genes known to confer antibiotic
resistance, with many isolates also showing phenotypic resistance to one or more of the
antibiotics tested. Only in a couple of instances was there a discrepancy between the
phenotypic resistance patterns and the presence of acquired AMR genes. However,
since the genomes presented within this paper are not closed, it is possible that genes
are present in regions of the genome currently unassembled. Further, the presence of
point mutations giving rise to resistance were not assessed and could thus offer
alternative resistance strategies.
The results presented here provide evidence that low concentrations of manuka
honey can inhibit the growth of clinical isolates of S. pseudintermedius, with a bacte-
ricidal mode of action. All isolates displayed sensitivity to manuka honey and had a
range of sensitivities to the conventional antibiotics tested. This is in line with previous
studies, which have demonstrated that manuka honey can inhibit S. aureus, MRSA, and
vancomycin-intermediate S. aureus (VISA) at low concentrations (31–33). The only study
looking at the ability of manuka honey to inhibit S. pseudintermedius was by Uri et al.
(34), and that study showed a low level of antibacterial activity. However, this was likely
due to issues with the homogeneity of the honey solution used in the study, as
highlighted by the authors of that paper, and not a true reflection of manuka honey
efficacy, particularly given the many in vitro and in vivo studies showing efficacy against
other bacterial species (11, 13, 21).
The results of the antibiotic susceptibility testing presented here reflect the general
trend of increased antimicrobial resistance seen globally, with 88% of the isolates
tested displaying resistance to two or more of the antibiotics (Fig. 2). The levels of
resistance for gentamicin and chloramphenicol presented here are broadly similar to
findings from earlier studies, where S. pseudintermedius resistance to chloramphenicol
and gentamicin was 75 and 55%, respectively, whereas the levels of resistance for
tetracycline were lower in this study (at 50%) than those previously reported (94.2%)
(35, 36). There were only four MRSP isolates within our collection, a lower incidence of
resistance than previously reported (35, 36).
In addition to obtaining the sensitivity profiles of these bacteria, and in view of the
growing interest in the use of topical and combination therapies for staphylococcal
infections (37), the ability of manuka honey to enhance antibiotic activity was tested.
Our results highlight how sublethal concentrations of honey are capable of significantly
improving (P  0.05) the activity of antibiotics from a variety of classes, for most isolates
tested (Fig. 2). The exception to this was oxacillin, for which combination with honey
showed no improvement in activity against any of the MRSP isolates. Importantly, in six
of the methicillin-susceptible S. pseudintermedius (MSSP) isolates, manuka honey was
associated with a significant decrease in the efficacy of oxacillin, although the isolates
did remain sensitive to oxacillin according to the breakpoints. This was an unexpected
finding, as previous studies have identified synergy between honey and oxacillin when
tested against MRSA, as well as reporting a possible mechanism of action for this
synergy through the MecR1 pathway (32, 38). It is interesting to note that synergy has
been observed for MRSA with the mecA mechanism of resistance previously, and the
four MRSPs here all have resistance mediated by mecA (Table S1), the same as seen in
the MRSA, so a similar response would have been expected.
This difference in response could be investigated further in future work. That the
isolates with the altered response are phenotypically methicillin sensitive, and therefore
unlikely to contain a functioning mecR1 gene, highlights why the response is different
from that previously observed. The mecR1 gene has not been shown to be common
within S. pseudintermedius isolates, with a recent study only detecting it in 7 of 17
isolates tested (39). It has also been observed that some MRSP isolates do not contain
mecR1 (40), again showing that even where isolates do have phenotypic resistance to
penicillin, honey may not be able to act on them via the previously described MecR1
pathway. The observed reduction in sensitivity to oxacillin upon concurrent exposure
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to sublethal concentrations of manuka honey is an important observation for medical
practice, where oxacillin is a commonly used treatment, as it suggests that using
manuka honey in combination with the other antibiotics tested here would be more
effective than oxacillin as part of a potential combination therapy. Our observation also
highlights the need, previously stressed within the O’Neill report (26), for novel bedside
diagnostic tools in order to better determine suitable treatments for patients present-
ing with infection. If clinicians are able to rapidly distinguish between opportunistic
infections caused by S. aureus and S. pseudintermedius, then suitable combination
therapies can be selected, improving clinical outcome and reducing the opportunity for
microbial persistence. Within veterinary practice, where S. pseudintermedius infection is
more commonly encountered, oxacillin is not considered for first line treatment of skin
infections (41) and thus our observation is of less significance. It should also be noted
that our data did not show decreased susceptibility to penicillin, indicating that
manuka honey/oxacillin combination therapies may not be suitable for treatment of S.
pseudintermedius, though this is unlikely to be the case for all penicillin. Investigation
into the mechanism by which honey is inhibiting S. pseudintermedius infection might
shed light onto why there is this discrepancy between S. pseudintermedius and S. aureus
when treated with oxacillin and honey; genetic variation between the two species
might account for the reduced efficacy of the combination in this case. Despite this, and
given the high levels of antibiotic resistance increasingly reported, the results pre-
sented here show there is real potential for honey to be used alone or as a topical
adjuvant to certain antibiotic treatments to help improve antibiotic efficacy against S.
pseudintermedius infections.
Alongside investigation of synergy, antivirulence compounds are of great interest as
they reduce pathogenicity while leaving bacterial growth unaffected and desirable host
microbes unharmed (42). As S. pseudintermedius strains are known to produce a range
of virulence factors that enhance their ability to cause severe disease in both animals
and humans (23, 43), the effect of sublethal concentrations of manuka honey on the
activity of virulence factors in S. pseudintermedius was tested. Investigating the effect of
sublethal concentrations of honey on virulence provided novel evidence that honey
can significantly reduce virulence factor activity in some S. pseudintermedius isolates
(Fig. 3). In infection, the ability to produce an extensive array of virulence factors allows
bacteria to break down host tissue, evade the immune system, and acquire host
nutrients (5, 44). The isolates in this study all displayed various levels of  hemolytic,
protease, and DNase activity, as well as the ability to auto-agglutinate. They were all
negative for lipase and lecithinase activity, correlating well with previous findings
charting the virulence profiles of S. pseudintermedius isolates from humans and dogs
(45). The data presented here establishes that sublethal concentrations of honey
significantly reduced hemolysin activity in half the S. pseudintermedius isolates tested,
indicating a strain-specific mode of action. As there was a significant increase in
hemolytic activity of one isolate, further work would be needed before this could be
considered of interest in a clinical setting. To date, there is little evidence of the role of
-hemolysin in S. pseudintermedius pathogenicity. In S. aureus, -hemolysin production
promotes efficient skin colonization (46). It is also thought to cause host cell cytotox-
icity, act as a biofilm ligase, and confer a selective advantage to those strains which
produce it (47). It is thus logical to suggest the ability of honey to reduce  hemolytic
activity would thereby reduce the capability of S. pseudintermedius to colonize host
cells and cause cytotoxicity and reduce zoonotic transmission.
Similarly, the results presented here show that sublethal doses of manuka honey
significantly reduce the ability of half the S. pseudintermedius strains to produce
protease and did not increase protease activity in any of the other strains. As the ability
of staphylococci to produce proteases has been linked to their ability to evade host
immunity, as well as cleaving host proteins and contributing to bacterial dissemination
within the host (48, 49), reduction in this activity could be clinically relevant. Previously
published work showed that protease null mutants of S. aureus have decreased
virulence and reduced dissemination and invasion in vivo (50). S. pseudintermedius
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produces a similar range of proteases and, if they perform an analogous role to those
seen in S. aureus, then honey could have an important function in decreasing the
severity of localized infection and reducing the spread of S. pseudintermedius within the
host.
Linked to infection duration and antibiotic tolerance is DNase activity, which has
been reported to aid in the formation of bacteria aggregates, maintenance of biofilm
(51), and degradation of neutrophil extracellular traps (52). These actions all assist the
bacteria in evading the immune system. The reduction of DNase activity seen in over
half the S. pseudintermedius tested (13/18) again suggests a role for manuka honey in
reducing bacterial virulence and supporting host function in infection. It is possible that
the significant decrease in DNase activity after treatment with sub-MIC honey in this
study could be related to the significant reduction in aggregation also observed. The
ability to agglutinate has been linked to the ability of isolates to form biofilms, an
important mechanism of persistence (53).
Aggregation is known to be partially dependent on components displayed on the
cell surface (54), but the role of DNase in Staphylococcus aggregation is less well
understood. Some studies observed increased expression of DNase from planktonic
cells (55), while others describe increased expression of DNase from sessile cells (56). It
has been shown that the presence of extracellular DNA (eDNA) improves the ability of
bacteria to aggregate and adhere to surfaces (57), therefore a reduction in DNase
expression would be expected to lead to increased aggregation. As exposure to
sublethal concentrations of manuka honey led to a reduction in both DNase activity
and bacterial aggregation, there could well be additional factors at work here. Further
work to elucidate the mechanisms which cause these effects needs to be undertaken.
The ability to form, and persist within, biofilms is a known Staphylococcus virulence
trait which decreases the susceptibility of in vivo populations to antimicrobial treatment
and provides a reservoir for systemic infection (58). Significant effort has been dedi-
cated to removing and inactivating the biofilms of S. aureus and S. epidermidis, with
manuka honey showing significant promise in both species (11, 59, 60). The data
presented here suggests that S. pseudintermedius isolates are likely no exception to this
trend, with all the isolates within our collection showing a statistically significant
reduction in mature biofilm biomass at manuka honey concentrations of 30% (wt/
vol). This suggests that manuka honey is able to disperse preformed biofilms and that
individual individual shed from the biofilms will rapidly succumb to the antimicrobial
effects that manuka honey showed against planktonic populations.
The data presented show that in vitro manuka honey is able to reduce the activity
of the virulence factors tested; however, caution should be used when interpreting the
data as the changes seen in vitro might not be replicated in vivo. Although the activity
assays used within this study allow investigators to measure differences in activity of
the supernatant, this technique has limitations as it does not distinguish between an
alteration in activity due to changes in protein efficiency versus effects produced by
changes in gene expression and/or protein production. In order to provide more
information about the exact mechanism of virulence factor modulation by manuka
honey, the techniques used here must be combined with an analysis of gene presence
(whole-genome sequencing [WGS]), gene expression (quantitative PCR [qPCR] and
RNAseq), and protein expression (2D gel electrophoresis and mass spectrometry). These
additional analyses, while outside the scope of the current work, would be of significant
interest to help elucidate manuka honey’s mechanism of activity against S. pseudinter-
medius. Further in vivo testing will be required to ensure that significant reductions in
activity highlighted here translate to a biological difference in the virulence of the
bacteria within animals and humans.
It is clear from the results presented here that manuka honey alone can effectively
inhibit antibiotic-sensitive and resistant S. pseudintermedius at low concentrations and,
when combined with selected antibiotics, can increase their efficacy. It is also apparent
that the addition of sublethal doses of manuka honey to S. pseudintermedius has
multiple effects on the virulence activity of those isolates, with over half seeing a
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significant reduction in virulence activity in vitro. S. pseudintermedius is recognized as a
major cause of postoperative infections in small animals and, more recently, as a
colonizer and opportunistic pathogen of humans (6). Our data indicate that use of
manuka honey in clinical treatment against S. pseudintermedius infections could be
possible and that manuka honey could potentially be used as an antibiotic adjuvant for
difficult-to-treat multiantibiotic resistant strains. Further investigation via broth mi-
crodilution on the effect of manuka honey on antibiotic sensitivity would help deter-
mine which interactions are antagonistic, indifferent, or synergistic. In addition, there is
strong evidence that manuka honey could function as a topical antivirulence treatment
to help reduce the severity of S. pseudintermedius infections and limit further coloni-
zation. Investigations into the mechanisms by which manuka honey is eliciting these
effects needs to be undertaken to determine the mechanistic processes and strain-
specific effects observed.
MATERIALS AND METHODS
Strains and culture conditions. Eighteen S. pseudintermedius isolates from dogs were used through-
out this study. All were provided by Nottingham Veterinary School, UK (18 isolates). These cultures were
stored at 80°C on cryobeads and revived onto Muller-Hinton agar (MHA) (Oxoid, UK) at 37°C before
testing. Throughout the experiments, Mueller-Hinton broth (MHB) was used where liquid medium was
required.
Antimicrobial agents. Sterile medical-grade manuka honey (Derma Sciences, Medihoney) was used
throughout and was a gift from Derma Sciences, Europe. Antimicrobial susceptibility testing discs of
penicillin (1 unit), tetracycline (30 g), chloramphenicol (30 g), gentamicin (10 g), and oxacillin (1 g)
were purchased from Oxoid (Hampshire, UK). These concentrations were chosen to match break points
in the EUCAST breakpoint tables.
DNA extraction/sequencing. DNA was extracted from cultures using the Qiagen DNAeasy kit
according to the manufacturer’s guidelines prior to quantifying yield and quality using spectrophoto-
metric and fluorometric methods. DNA libraries for sequencing were constructed using the Illumina
Nextera XT kit and sequenced on an Illumina MiSeq platform using a V3 reagent kit and 2  300 bp reads.
Genome assembly and analysis. Raw sequence reads were passed through cutadapt (v2.0) (61) for
the removal of nextera sequence adapters only prior to genome assembly using SPAdes (v3.12.0) in
careful mode with read error correction and auto k-mer detection (62). Quast (v5.0.0) (63) was used to
assess the quality of the genome assemblies. MLST allele sequences, IDs, and isolate STs were queried
against the genome assemblies using the MLST tool (v2.16) (currently unpublished, T. Seemann, mlst
[Github, https://github.com/tseemann/mlst ]). A core SNP phylogeny was reconstructed using the isolates
from this study along with 137 S. pseudintermedius genome assemblies obtained from NCBI and using
variant sites called by SNIPPY (v4.3.2) (currently unpublished, T. Seemann, SNIPPY [Github, https://github
.com/tseemann/SNIPPY ]). Recombination was accounted for with the use of Gubbins (v 2.3.1) (64) prior
to inference of a maximum-likelihood phylogenetic tree using FastTree (v 2.1.10), applying the gener-
alized time-reversible model (gtr) (65). A final tree was annotated with the use of iTOL (66). The presence
of antimicrobial resistance genes was determined using ABRICATE (v0.8.11) (T. Seemann, Abricate
[Github, https://github.com/tseemann/abricate ]). A threshold of 90% sequence identity was used to
determine a good match between the database genes and hits within the genome sequences.
Minimum inhibitory/bactericidal concentration testing. MICs of manuka honey antimicrobial
susceptibility were assessed using an adapted European Committee on Antimicrobial Susceptibility
Testing methodology. Briefly, mid-log-phase cells were diluted to 0.5 McFarland standard diluted 1 in 100
before it was mixed 1:1 with MHB to a final volume of 200 l (creating a cell density of 5  105 CFU/ml)
with the manuka honey set out as 2% (wt/vol) increments, diluted in MHB. The isolates were then grown
for a period of 16 to 20 h at 37°C before measurement of optical density at a wavelength of 600 nm
(OD600). The MIC was considered to be the lowest concentration which inhibited cell growth (defined as
blank-corrected OD600 measurements equaling 0). The minimum bactericidal concentration (MBC) was
determined by plating 10 l of cells onto MHA from all wells showing no growth at 18 h and incubating
for a further 18 h at 37°C. The MBC was defined as the lowest concentration that reduced the viability
of the initial bacterial inoculum by 99.9%. Positive-control wells contained growth medium and
bacterial cells with no antibiotic or honey, negative-control wells (used for blank correction) contained
growth medium and no cells.
Antibiotic disc susceptibility. Susceptibility of isolates to antibiotics alone and in combination with
sublethal concentrations of manuka honey was determined using disc diffusion on MHA. Briefly, the cells
were diluted to 0.5 McFarland standard and then, using a sterile cotton swab, a lawn plate was created
and antibiotic discs were immediately applied using sterile forceps. The plates were incubated for 16 to
20 h at 37°C before the diameter of the zones of inhibition was measured. Zone sizes were interpreted
using EUCAST Clinical Breakpoint Tables v. 9.0; where S. pseudintermedius breakpoints were unavailable,
those for S. aureus were used. To screen for potential synergy between antibiotics and honey, the disc
diffusion assay was repeated with MHA supplemented poststerilization with a sublethal dose of 5%
(wt/vol) manuka honey.
Virulence testing. All isolates were screened for their ability to produce the virulence factors
hemolysin, protease, lipase, lecithinase, and DNase. Agar plates were prepared by supplementing MHA
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with either 5% (vol/vol) sheep blood, 5% (vol/vol) skim milk powder, or 5% (vol/vol) egg yolk (Sigma, UK).
Supplements were added after the medium had been autoclaved and were mixed before pouring into
plates. DNase agar was purchased directly from Sigma and prepared following the manufacturer’s
guidelines. Prior to use, the plates were equilibrated to room temperature and 5-mm diameter wells were
cut in the agar surface using a sterile cork borer. Overnight cultures were diluted to a density of OD600
0.8 to 1.0 (equivalent to a cell density of 1  108 CFU/ml) and pelleted before resuspension in 0.4%
MHA, with or without 5% (wt/vol) honey. A volume of 100 l of this adjusted cell suspension was added
to the plate wells and the plates cooled quickly to allow the soft agar to rapidly set and form a plug
within the well. The plates were then incubated for 24 h at 37°C and a zone of activity around bacterial
growth was recorded as a positive result for each virulence factor.
Auto-aggregation. To assess aggregation, overnight cultures were adjusted to OD600 0.9 and then
1 ml was transferred to a 1.5-ml Eppendorf tube, centrifuged at 14,000  g for 5 min, and the pellet
resuspended in 1 ml of phosphate-buffered saline (PBS) (Oxoid, UK) or PBS  honey (5% [wt/vol]). The
inoculum was then transferred to microcuvettes and the OD600 measured at 0 and 24 h with static
incubation at room temperature between the measurements. Bacterial cells that strongly agglutinate do
not remain in the aqueous phase, leading to a decrease in the OD600, whereas cells prevented from
agglutinating show an OD600 that remains relatively stable. The percentage change of OD600 was
calculated after 24 h. Viable cell counts were taken using the Miles Misra method before and after
incubation to confirm that any differences in auto-aggregation were not due to cell death or prolifer-
ation.
Biofilm assessment. To determine the effect of manuka honey on mature biofilm, S. pseudinterme-
dius strains were diluted as described for MIC testing and diluted 1:1 with MHB to a final volume of 200 l
before incubating for 24 h at 37°C to allow biofilm formation. Following incubation, the supernatant was
removed carefully from the wells, so as not to disturb the biofilm, and washed once with sterile PBS.
Manuka honey was diluted to concentrations of 10% to 50% (wt/vol) (in increments of 10%) in MHB. A
volume of 200 l of these solutions was added to the biofilms before incubating for a further 24 h at
37°C. Following incubation, supernatant was removed and wells gently rinsed twice with PBS before
fixing remaining biofilms with methanol for 15 min and staining with crystal violet (1% [vol/vol] diluted
in distilled water) for 15 min. Excess stain was rinsed until water ran clear and wells were dried before
adding 7% acetic acid (diluted in distilled water) for 15 min to dissolve the bound crystal violet.
Absorbance was measured at a wavelength of 590 nm.
The ability of the S. pseudintermedius strains to attach to surfaces and form biofilm was performed
following the method and classification proposed by Stepanovic et al. (22). Biofilm cultures were
established, fixed, and stained as described above and then classified as weakly, moderately, or strongly
adherent, based upon the following formula: ODC  OD  2 ODC  weak adherence; 2 ODC 
OD  4 ODC  moderate adherence; and 4 ODC  OD  strong adherence. ODC was defined as three
standard deviations above the mean OD of the negative (medium only) control.
Statistical analysis. All tests were performed in triplicate; as data were nonparametric (determined
using a Shapiro-Wilk test), they were analyzed using the Mann-Whitney method (for auto-aggregation)
and the Kruskal Wallis method (for all other experiments) (GraphPad Prism 8). Unless otherwise stated,
all bars in figures show median values and error bars represent a 95% confidence limit.
Data availability. Sequencing reads and genome assemblies from this study are available from NCBI
via the BioProject record PRJNA561036.
Accession numbers are as follows: isolate A (SAMN12347716, SRR9998529), isolate B (SAMN12347717,
SRR9998521, SRR9998530), isolate C (SAMN12347718, SRR9998528, SRR9998519), isolate D
(SAMN12347719, SRR9998518), isolate E (SAMN12347720, SRR9998522), isolate F (SAMN12347721,
SRR9998525), isolate G (SAMN12347722, SRR9998517), isolate H (SAMN12347723, SRR9998524), isolate I
(SAMN12347724, SRR9998523), isolate J (SAMN12347725, SRR9998520), isolate K (SAMN12347726,
SRR9998533), isolate M (SAMN12347727, SRR9998534), isolate N (SAMN12347728, SRR9998535), isolate
O (SAMN12347729, SRR9998536), isolate P (SAMN12347730, SRR9998526, SRR9998527), isolate Q
(SAMN12347731, SRR9998531), isolate T (SAMN12347732, SRR9998516), isolate X (SAMN12347733,
SRR9998532).
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